Kala Pharmaceuticals Inc (KALA) — Cash Flow-to-Debt Ratio
Kala Pharmaceuticals Inc (KALA) has a Cash Flow-to-Debt Ratio of -1.83x as of March 2026, meaning its operating cash flow of $-4.56 Million could theoretically repay -2% of its total liabilities ($2.49 Million) in one year. See how liquid is Kala Pharmaceuticals Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kala Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Kala Pharmaceuticals Inc across 13 annual periods. Also explore KALA shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Kala Pharmaceuticals Inc (2013–2025)
Year-by-year debt coverage analysis for Kala Pharmaceuticals Inc. For market capitalisation and broader financial context, see market value of Kala Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -12.83x | $-31.99 Million | $2.49 Million | ▼ -1783.8% |
| 2024 | -0.68x | $-29.38 Million | $43.15 Million | ▼ -18.1% |
| 2023 | -0.58x | $-27.93 Million | $48.45 Million | ▲ +50.4% |
| 2022 | -1.16x | $-78.91 Million | $67.85 Million | ▼ -31.8% |
| 2021 | -0.88x | $-108.23 Million | $122.62 Million | ▼ -18.4% |
| 2020 | -0.75x | $-90.69 Million | $121.61 Million | ▼ -0.2% |
| 2019 | -0.74x | $-92.72 Million | $124.63 Million | ▼ -59.4% |
| 2018 | -0.47x | $-54.12 Million | $115.98 Million | ▲ +63.8% |
| 2017 | -1.29x | $-34.10 Million | $26.45 Million | ▼ -532.0% |
| 2016 | -0.20x | $-27.35 Million | $134.09 Million | ▲ +80.8% |
| 2015 | -1.06x | $-15.09 Million | $14.24 Million | ▲ +41.6% |
| 2014 | -1.82x | $-15.36 Million | $8.46 Million | ▼ -15.1% |
| 2013 | -1.58x | $-10.84 Million | $6.87 Million | — |